229 related articles for article (PubMed ID: 35950385)
1. [Correlation between metabolic syndrome and prognosis of patients with clear cell renal cell carcinoma].
Zuo MN; DU YQ; Yu LP; Dai X; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):636-643. PubMed ID: 35950385
[TBL] [Abstract][Full Text] [Related]
2. Influence of metabolic syndrome on survival of patients with localized renal clear cell carcinoma: A retrospective cohort study in China.
Liang Y; Zhang C; Luo J; He Y; Zhang Y; Quan Z; Yang L
Urol Oncol; 2023 May; 41(5):257.e19-257.e26. PubMed ID: 36967252
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma.
Kriegmair MC; Mandel P; Porubsky S; Dürr J; Huck N; Nuhn P; Pfalzgraf D; Michel MS; Wagener N
Horm Cancer; 2017 Apr; 8(2):127-134. PubMed ID: 28247362
[TBL] [Abstract][Full Text] [Related]
4. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
[TBL] [Abstract][Full Text] [Related]
5. Multicenter Study of Controlling Nutritional Status (CONUT) Score as a Prognostic Factor in Patients With HIV-Related Renal Cell Carcinoma.
Xue W; Zhang Y; Wang H; Zhang Y; Hu X
Front Immunol; 2021; 12():778746. PubMed ID: 34917092
[TBL] [Abstract][Full Text] [Related]
6. Impact of tumor size on patient survival after radical nephrectomy for pathological T3a renal cell carcinoma.
Sugiyama Y; Yatsuda J; Murakami Y; Ito N; Yamasaki T; Mikami Y; Ogawa O; Kamba T
Jpn J Clin Oncol; 2019 May; 49(5):465-472. PubMed ID: 30793163
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity.
Luo Y; Feng B; Wei D; Han Y; Li M; Zhao J; Lin Y; Hou Z; Jiang Y
Sci Rep; 2020 Oct; 10(1):17674. PubMed ID: 33077839
[TBL] [Abstract][Full Text] [Related]
8. De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study.
Lee H; Lee SE; Byun SS; Kim HH; Kwak C; Hong SK
BJU Int; 2017 Feb; 119(2):261-267. PubMed ID: 27226065
[TBL] [Abstract][Full Text] [Related]
9. Metabolic syndrome is associated with improved cancer-specific survival in patients with localized clear cell renal cell carcinoma.
Liu Z; Wang H; Zhang L; Li S; Fan Y; Meng Y; Hu S; Zhang Q; He Z; Zhou L; Han W; Yu W; Jin J
Transl Androl Urol; 2019 Oct; 8(5):507-518. PubMed ID: 31807427
[TBL] [Abstract][Full Text] [Related]
10. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
[TBL] [Abstract][Full Text] [Related]
11. Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study.
Kim SH; Lee DE; Joung JY; Seo HK; Lee KH; Chung J
Investig Clin Urol; 2020 Mar; 61(2):146-157. PubMed ID: 32158965
[TBL] [Abstract][Full Text] [Related]
12. Local ablation vs partial nephrectomy in T1N0M0 renal cell carcinoma: An inverse probability of treatment weighting analysis.
Shi L; He Y; Liu C; Qian X; Wang Z
Cancer Med; 2020 Nov; 9(21):7988-8003. PubMed ID: 32888392
[TBL] [Abstract][Full Text] [Related]
13. Leibovich score is the optimal clinico-pathological system associated with recurrence of non-metastatic clear cell renal cell carcinoma.
Blackmur JP; Gaba F; Fernando D; Williams S; O'Donnell M; McNeill A; Stewart GD; Leung S; Laird A
Urol Oncol; 2021 Jul; 39(7):438.e11-438.e21. PubMed ID: 34023196
[TBL] [Abstract][Full Text] [Related]
14. Survival benefits analyses of T1a renal cell carcinoma patients treated with microwave ablation.
Hou Q; Yu X; Cheng Z; Han Z; Liu F; Dou J; Yu J; Liang P
Eur J Radiol; 2021 Nov; 144():109951. PubMed ID: 34607288
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Sarcopenia and Albumin in the Surgical Management of Localized Renal Cell Carcinoma.
Midenberg E; Higgins MI; Schmeusser BN; Patil DH; Zaldumbide J; Martini DJ; Steele S; Williams M; Nabavizadeh R; Psutka SP; Ogan K; Bilen MA; Master VA
Urol Oncol; 2023 Jan; 41(1):50.e19-50.e26. PubMed ID: 36280529
[TBL] [Abstract][Full Text] [Related]
16. Karnofsky performance status predicts overall survival, cancer-specific survival, and progression-free survival following radical cystectomy for urothelial carcinoma.
Evers PD; Logan JE; Sills V; Chin AI
World J Urol; 2014 Apr; 32(2):385-91. PubMed ID: 23756991
[TBL] [Abstract][Full Text] [Related]
17. Preoperative apolipoprotein B/A1 ratio is an independent prognostic factor in metastatic renal cell carcinoma.
Zhang F; Xie Y; Ma X; Gu L; Li H; Li X; Guo G; Zhang X
Urol Oncol; 2019 Mar; 37(3):184.e9-184.e17. PubMed ID: 30509867
[TBL] [Abstract][Full Text] [Related]
18. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
[TBL] [Abstract][Full Text] [Related]
19. 2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race.
Schmeusser BN; Patil DH; Nicaise EH; Armas-Phan M; Nabavizadeh R; Narayan VM; Joshi SS; Ogan K; Osunkoya AO; Bilen MA; Master VA
Cancer; 2024 Feb; 130(3):453-466. PubMed ID: 37803521
[TBL] [Abstract][Full Text] [Related]
20. Comparison of prognosis between patients undergoing radical nephrectomy versus partial nephrectomy for renal cell carcinoma ≤7 cm T3aN0/xM0: Survival benefit is biased toward partial nephrectomy.
Liu S; Feng C; Liu C; Wang Z
Cancer Med; 2021 Dec; 10(24):8909-8923. PubMed ID: 34779154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
